Heerfordt Ida M, Framke Elisabeth, Windfeld-Mathiasen Josefine, Mogensen Mette, Olsen Rasmus Huan, Magyari Melinda, Horwitz Henrik
Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.
J Dermatol. 2024 Aug;51(8):1113-1116. doi: 10.1111/1346-8138.17338. Epub 2024 Jun 11.
Interferon-beta has been suggested as a trigger of psoriasis, yet a systematic investigation is lacking. This study aimed to assess the risk of developing psoriasis following interferon-beta treatment, utilizing a pharmaco-epidemiological approach to investigate the role of interferon-beta in psoriasis pathogenesis. We included all treatment-naïve patients with multiple sclerosis (MS) in Denmark who initiated interferon-beta treatment for MS from January 1996 to June 2023. These patients were compared to a control cohort of patients with MS treated with other disease-modifying drugs. We compared the incidence rates of psoriasis before and during the treatment. Data for this study were extracted from the Danish MS Registry and integrated with information from other national Danish health registries. Among 7174 patients treated with interferon-beta, the incidence rate of psoriasis post-treatment initiation was slightly higher (2.01 per 1000 person-years) compared to the rate prior to treatment (1.67 per 1000 person-years). This increase did not achieve statistical significance (P = 0.53), with an incidence rate ratio (IRR) of 1.20 (95% confidence interval [CI] 0.68-2.13). The control cohort showed an increase in psoriasis incidence post-treatment initiation (3.12 per 1000 person-years) compared to prior (1.11 per 1000 person-years), with an IRR of 2.80 (95% CI 1.36-4.77, P = 0.0038). This registry-based self-controlled study does not support the theory that interferon-beta acts as a trigger for psoriasis development.
已有研究表明β-干扰素是银屑病的诱发因素，但缺乏系统性调查。本研究旨在通过药物流行病学方法评估β-干扰素治疗后发生银屑病的风险，以探究β-干扰素在银屑病发病机制中的作用。我们纳入了丹麦所有1996年1月至2023年6月开始接受β-干扰素治疗的初治多发性硬化症（MS）患者。将这些患者与接受其他疾病修饰药物治疗的MS患者对照队列进行比较。我们比较了治疗前和治疗期间银屑病的发病率。本研究数据取自丹麦MS登记处，并与丹麦其他国家卫生登记处的信息相结合。在7174例接受β-干扰素治疗的患者中，治疗开始后的银屑病发病率（每1000人年2.01例）略高于治疗前（每1000人年1.67例）。这种增加未达到统计学显著性（P = 0.53），发病率比（IRR）为1.20（95%置信区间[CI] 0.68 - 2.13）。对照队列显示治疗开始后的银屑病发病率（每1000人年3.12例）高于治疗前（每1000人年1.11例），IRR为2.80（95% CI 1.36 - 4.77，P = 0.0038）。这项基于登记处的自身对照研究不支持β-干扰素是银屑病发病诱因的理论。
